Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
grade B 53.79 -0.81% -0.44
EBS closed down 0.81 percent on Wednesday, October 16, 2019, on 83 percent of normal volume.

Earnings due: Nov 7

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical EBS trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish -0.81%
20 DMA Support Bullish 2.52%
NR7 Range Contraction 2.52%
NR7-2 Range Contraction 2.52%
20 DMA Support Bullish 2.30%
NR7 Range Contraction 2.30%
Up 3 Days in a Row Strength 2.30%
Crossed Above 20 DMA Bullish 2.46%
20 DMA Resistance Bearish 3.18%

Older signals for EBS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.
Medicine Medical Specialties Pharmaceutical Drugs Solid Tumors Rheumatoid Arthritis Influenza Inflammatory Bowel Disease Vaccination FDA Chronic Lymphocytic Leukemia Vaccines Biological Warfare Anthrax Chemical Warfare Agents Preclinical Preclinical Product
Is EBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 73.89
52 Week Low 39.11
Average Volume 444,545
200-Day Moving Average 51.1768
50-Day Moving Average 49.3972
20-Day Moving Average 52.409
10-Day Moving Average 53.144
Average True Range 1.7977
ADX 12.55
+DI 25.1471
-DI 18.5251
Chandelier Exit (Long, 3 ATRs ) 49.5068
Chandelier Exit (Short, 3 ATRs ) 55.2031
Upper Bollinger Band 54.5634
Lower Bollinger Band 50.2546
Percent B (%b) 0.82
BandWidth 8.221489
MACD Line 0.8818
MACD Signal Line 0.9938
MACD Histogram -0.112
Fundamentals Value
Market Cap 2.21 Billion
Num Shares 41.1 Million
EPS 1.57
Price-to-Earnings (P/E) Ratio 34.26
Price-to-Sales 3.22
Price-to-Book 2.65
PEG Ratio 1.56
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.05
Resistance 3 (R3) 56.17 55.54 55.68
Resistance 2 (R2) 55.54 54.96 55.48 55.55
Resistance 1 (R1) 54.66 54.60 54.34 54.54 55.43
Pivot Point 54.03 54.03 53.87 53.97 54.03
Support 1 (S1) 53.15 53.45 52.84 53.04 52.15
Support 2 (S2) 52.52 53.09 52.46 52.03
Support 3 (S3) 51.64 52.52 51.90
Support 4 (S4) 51.53